![Mark Chin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Chin
Direktor/Vorstandsmitglied bei
DISC MEDICINE, INC.
Vermögen: - $ am 31.07.2026
Profil
Mark Chin is currently Director at Optikira LLC, Depixus SAS, Iterum Therapeutics International Ltd., Iterum Therapeutics US Holding Ltd., Ensoma, Inc., and Partner at Avoro Ventures LLC and Avoro Capital LP.
Since 2021, Director at Disc Medicine Opco, Inc. and Independent Director at Disc Medicine, Inc. Formerly Independent Director at Iterum Therapeutics Plc (2017–2023), Imara, Inc. (2019–2023), and Harpoon Therapeutics, Inc. (2017–2024).
Former Director at VelosBio, Inc., Pyxis Oncology, Inc. (2021–2022), Gemini Therapeutics, Inc., Aura Biosciences, Inc. (2016–2020), and Managing Director at Arix Bioscience Plc (2020–2023) and Arix Bioscience (2016–2020).
Principal at Longitude Capital (2012–2016) and Gilead Sciences, Inc. Consultant at The Boston Consulting Group, Inc. (2011–2012).
Manager at Professional Services and Genentech Ventures, Inc. Education includes graduate degree from the University of Pennsylvania, undergraduate degree from the University of California San Diego, and MBA from The Wharton School of the University of Pennsylvania.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DISC MEDICINE, INC. -.--% | 18.06.2026 | 0 ( -.--% ) | - $ | 31.07.2026 |
Aktive Positionen von Mark Chin
| Unternehmen | Position | Beginn |
|---|---|---|
| DISC MEDICINE, INC. | Direktor/Vorstandsmitglied | 01.09.2021 |
Iterum Therapeutics International Ltd.
 Iterum Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Develops clinical-stage pharmaceutical products | Direktor/Vorstandsmitglied | - |
Avoro Ventures LLC
 Avoro Ventures LLC Investment ManagersFinance Avoro Ventures invests in public and private companies located in the United States. The firm focuses on life sciences and biotechnology. It participates in seed, early, and late stage transactions. | Private Equity Investor | 01.12.2023 |
Ensoma, Inc.
 Ensoma, Inc. Medical SpecialtiesHealth Technology Operates as a clinical-stage genomic vivo cellular medicines company | Direktor/Vorstandsmitglied | - |
Disc Medicine Opco, Inc.
 Disc Medicine Opco, Inc. Miscellaneous Commercial ServicesCommercial Services Develops therapies for hematologic diseases | Direktor/Vorstandsmitglied | 01.09.2021 |
Depixus SAS
 Depixus SAS Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops a technology for genetic and epigenetic analysis | Direktor/Vorstandsmitglied | - |
Iterum Therapeutics US Holding Ltd.
 Iterum Therapeutics US Holding Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Direktor/Vorstandsmitglied | - |
Optikira LLC
 Optikira LLC BiotechnologyHealth Technology Develops novel therapeutics | Direktor/Vorstandsmitglied | - |
Avoro Capital LP
 Avoro Capital LP Financial ConglomeratesFinance Provides investment services | Corporate Officer/Principal | 01.11.2023 |
Ehemalige bekannte Positionen von Mark Chin
| Unternehmen | Position | Ende |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Mark Chin
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
59
Beziehungen ersten Grades
26
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 26 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Aura Biosciences, Inc.
 Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications | Health Technology |
Optikira LLC
Optikira LLC BiotechnologyHealth Technology Develops novel therapeutics | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Commercial Services |
Professional Services
 Professional Services Information Technology ServicesTechnology Services Provides network security consulting services | Technology Services |
University of California San Diego
 University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genentech Ventures, Inc.
 Genentech Ventures, Inc. Investment ManagersFinance Genentech Ventures invests in companies located in the United States. The firm focuses on biopharmaceuticals and biotechnology sectors. It participates in early stage transactions. | Finance |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Iterum Therapeutics Plc
 Iterum Therapeutics Plc Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem | Health Technology |
Harpoon Therapeutics, Inc.
 Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage immunotherapy company that develops T-cell engagers to treat cancer and other diseases | Health Technology |
Imara, Inc.
 Imara, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes novel therapeutics for patients with sickle cell disease | Health Technology |
Arix Bioscience Plc
 Arix Bioscience Plc Investment ManagersFinance Operates as a global venture capital firm | Finance |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops a technology for genetic and epigenetic analysis | Commercial Services |
VelosBio, Inc.
 VelosBio, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in conducting biotechnological research activities | Commercial Services |
Iterum Therapeutics International Ltd.
Iterum Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Develops clinical-stage pharmaceutical products | Health Technology |
Iterum Therapeutics US Holding Ltd.
Iterum Therapeutics US Holding Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Avoro Capital LP
Avoro Capital LP Financial ConglomeratesFinance Provides investment services | Finance |
Pyxis Oncology, Inc.
 Pyxis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a preclinical oncology company focused on developing an arsenal of next-generation therapeutics | Health Technology |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. Miscellaneous Commercial ServicesCommercial Services Develops therapies for hematologic diseases | Commercial Services |
Ensoma, Inc.
Ensoma, Inc. Medical SpecialtiesHealth Technology Operates as a clinical-stage genomic vivo cellular medicines company | Health Technology |
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Develops drugs for dry age-related macular degeneration and associated rare genetic diseases | Health Technology |
Avoro Ventures LLC
Avoro Ventures LLC Investment ManagersFinance Avoro Ventures invests in public and private companies located in the United States. The firm focuses on life sciences and biotechnology. It participates in seed, early, and late stage transactions. | Finance |
Disc Medicine, Inc.
 Disc Medicine, Inc. BiotechnologyHealth Technology Develops therapies addressing red blood cell production in hematologic diseases | Health Technology |
Longitude Capital | |
Arix Bioscience /Venture Capital/
 Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience invests in companies located in the United Kingdom. The firm focuses on the therapeutics sector. It participates in early stage capital requirements. | Finance |
